ATE477495T1 - Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor - Google Patents

Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor

Info

Publication number
ATE477495T1
ATE477495T1 AT06738465T AT06738465T ATE477495T1 AT E477495 T1 ATE477495 T1 AT E477495T1 AT 06738465 T AT06738465 T AT 06738465T AT 06738465 T AT06738465 T AT 06738465T AT E477495 T1 ATE477495 T1 AT E477495T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
egfr kinase
methods
inhibition
emt
Prior art date
Application number
AT06738465T
Other languages
English (en)
Inventor
John Haley
Graeme Griffin
Lukas Amler
David Eberhard
Robert Yauch
Original Assignee
Osi Pharm Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc, Genentech Inc filed Critical Osi Pharm Inc
Application granted granted Critical
Publication of ATE477495T1 publication Critical patent/ATE477495T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT06738465T 2005-03-16 2006-03-16 Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor ATE477495T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66254505P 2005-03-16 2005-03-16
US67182105P 2005-04-15 2005-04-15
PCT/US2006/009403 WO2006101925A2 (en) 2005-03-16 2006-03-16 Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE477495T1 true ATE477495T1 (de) 2010-08-15

Family

ID=36586095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06738465T ATE477495T1 (de) 2005-03-16 2006-03-16 Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor

Country Status (7)

Country Link
US (3) US8093011B2 (de)
EP (1) EP1861715B1 (de)
JP (1) JP5085529B2 (de)
AT (1) ATE477495T1 (de)
CA (1) CA2601157A1 (de)
DE (1) DE602006016085D1 (de)
WO (1) WO2006101925A2 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070020A2 (en) * 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
ES2537631T3 (es) * 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
WO2006099396A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
EP1861715B1 (de) 2005-03-16 2010-08-11 OSI Pharmaceuticals, Inc. Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
ATE533057T1 (de) 2005-09-20 2011-11-15 Osi Pharm Inc Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
US9250243B2 (en) * 2006-09-21 2016-02-02 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
JP2010509370A (ja) * 2006-11-10 2010-03-25 シンダックス ファーマシューティカルズ，インク． 癌の治療用のＥＲα＋リガンドとヒストンデアセチラーゼ阻害剤との組み合わせ
KR100934706B1 (ko) * 2006-12-07 2009-12-31 재단법인서울대학교산학협력재단 Ｔｍ４ｓｆ５의 기능을 저해하는 항암물질의 스크리닝 방법및 칼콘계 화합물을 함유하는 항암조성물
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
US8377636B2 (en) * 2007-04-13 2013-02-19 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to kinase inhibitors
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
WO2009015203A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
AU2008286361B2 (en) * 2007-08-13 2013-09-26 Takeda Pharmaceutical Company Limited IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
EP2188393B1 (de) * 2007-08-14 2013-09-18 F. Hoffmann-La Roche AG Prognosemarker zur behandlung mit egfr-hemmern
BRPI0815545A2 (pt) 2007-08-14 2015-02-10 Hoffmann La Roche Marcadores preditivos para o tratamento com inibidores de egfr
EP2188392A1 (de) * 2007-08-14 2010-05-26 F. Hoffmann-Roche AG Prognosemarker zur behandlung mit egfr-hemmern
BRPI0815415A2 (pt) 2007-08-14 2015-02-03 Hoffmann La Roche Marcador preditivo para tratamento inibidor de egfr
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
EP2036576A1 (de) * 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B-Fibronektin als Stratifizierungsmarker für Antitumormittel
WO2009045389A2 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2694154A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2207892A4 (de) 2007-10-15 2010-12-08 Precision Therapeutics Inc Verfahren zur selektion aktiver agentien für die krebsbehandlung
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
EP2071336A1 (de) * 2007-12-13 2009-06-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Serumproteom zum Finden von diagnostischen Markern und zur Überwachung des therapeutischen Eingriffs bei der Behandlung von Leberzellenkarzinom
AU2009221808A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and EGFR antagonists
US7998688B2 (en) * 2008-03-07 2011-08-16 OSI Pharmaceuticals, LLC Inhibition of EMT induction in tumor cells by anti-cancer agents
US7951549B2 (en) * 2008-03-07 2011-05-31 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2009126310A2 (en) * 2008-04-10 2009-10-15 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
CA2721687A1 (en) * 2008-05-14 2009-11-19 Precision Therapeutics, Inc. Methods for predicting a patient's response to egfr inhibitors
US20100311084A1 (en) * 2008-05-14 2010-12-09 Precision Therapeutics, Inc. Methods for predicting a patient's response to egfr inhibitors
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010121238A2 (en) * 2009-04-17 2010-10-21 Translational Genomics Research Institute (Tgen) Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
WO2010120966A1 (en) * 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
AU2011223655A1 (en) * 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120095029A1 (en) * 2010-10-15 2012-04-19 Hoffmann-La Roche Inc. Ipp complex as marker for erlotinib treatment
US20140155397A1 (en) * 2011-04-01 2014-06-05 Board Of Regents Emt signatures and predictive markers and method of using the same
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
CA2838086A1 (en) 2011-06-02 2012-12-06 Almac Diagnostics Limited Molecular diagnostic test for cancer
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
WO2013055530A1 (en) 2011-09-30 2013-04-18 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
RU2017120287A (ru) 2012-02-28 2018-11-15 АйАрЭм ЭлЭлСи ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43
EP3441767B1 (de) 2012-03-28 2021-02-24 On-chip Biotechnologies Co., Ltd. Vorrichtung zur erkennung des malignitätsgrades einer zirkulierenden tumorzelleneinheit und kit dafür
KR20150023904A (ko) 2012-06-27 2015-03-05 버그 엘엘씨 전립선암의 진단 및 치료에서의 마커의 용도
US9618514B2 (en) 2012-09-17 2017-04-11 Agios Pharmaceuticals, Inc Methods of evaluating patients using E-cadherin and vimentin
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014087156A1 (en) 2012-12-03 2014-06-12 Almac Diagnostics Limited Molecular diagnostic test for cancer
US9782075B2 (en) 2013-03-15 2017-10-10 I2Dx, Inc. Electronic delivery of information in personalized medicine
US11089959B2 (en) 2013-03-15 2021-08-17 I2Dx, Inc. Electronic delivery of information in personalized medicine
WO2015104284A1 (en) * 2014-01-08 2015-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination
AU2015231053B2 (en) 2014-03-21 2019-04-11 Les Laboratoires Servier Compounds and their methods of use
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
JP6759229B2 (ja) 2014-12-08 2020-09-23 バーグ エルエルシー 前立腺癌の診断および処置におけるフィラミンａを含むマーカーの使用
US20180355321A1 (en) 2015-12-18 2018-12-13 Zeon Corporation Method for preparing adherent-type cells acclimated to suspension culture, method for inducing epithelial-mesenchymal transition in adherent-type epithelial cells, and use for methods
JP6789512B2 (ja) * 2016-05-10 2020-11-25 学校法人日本医科大学 肺癌治療のための抗癌剤の効果の検査法
JP7112660B2 (ja) * 2018-03-13 2022-08-04 アイ２ディーエックス インコーポレイテッド 個別化医療における情報の電子配信
CN113312056B (zh) * 2021-06-16 2022-04-19 浪潮云信息技术股份公司 angular大型集成项目的国际化实现方法、电子设备及存储介质

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
US5925519A (en) * 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
BR9814018A (pt) 1997-11-11 2000-09-26 Pfizer Prod Inc Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
IL139934A (en) 1998-05-29 2007-10-31 Sugen Inc History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
ES2161655B1 (es) 1999-07-01 2002-06-01 Consejo Superior Investigacion Procedimiento para determinar la capacidad invasiva y metastasica de un tumor epitelial mediante el uso de snail.
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
JP2005523688A (ja) 2002-01-18 2005-08-11 ブリストル−マイヤーズ　スクイブ　カンパニー タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
DK2261369T3 (da) 2002-03-13 2014-07-28 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
WO2003101491A1 (en) * 2002-06-03 2003-12-11 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
EP1803821B1 (de) 2002-06-05 2012-02-29 Cedars-Sinai Medical Center Verfahren zur Handhabung der Kinasehemmertherapie
WO2004000102A2 (en) 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
EP1570080A4 (de) * 2002-11-15 2006-03-01 Genomic Health Inc Genexpressionsprofilierung einer egfr-positiven krebserkrankung
CA2512536A1 (en) 2003-01-08 2004-07-29 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2004065602A1 (es) 2003-01-17 2004-08-05 Universidad Autónoma de Madrid Procedimiento para identificar la transición epitelio-mesenquimal de células mesoteliales (temcm) e identificar compuestos moduladores de temcm, composiciones farmacéuticas y su uso en el diagnóstico y tratamiento de enfermedades que cursan con temcm
CA2515096A1 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
JP3762975B2 (ja) * 2003-03-18 2006-04-05 学校法人慶應義塾 単球由来多能性細胞ｍｏｍｃ
WO2004111273A2 (en) 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
WO2005017493A2 (en) 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarkers in cancer
JP2007537717A (ja) 2004-01-07 2007-12-27 ブリストル−マイヤーズ　スクイブ　カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
WO2005070020A2 (en) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
JP2007530954A (ja) 2004-03-26 2007-11-01 ブリストル−マイヤーズ　スクイブ　カンパニー 非小細胞肺癌において上皮細胞増殖因子レセプターモジュレーターに対する感受性を決定するためのバイオマーカーおよび方法
WO2005107803A2 (en) 2004-05-06 2005-11-17 Vernalis Plc Methods of determining the prognosis and treatment of subjects with lung cancer
ES2537631T3 (es) 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
WO2006099396A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
EP1861715B1 (de) 2005-03-16 2010-08-11 OSI Pharmaceuticals, Inc. Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
AU2006287175A1 (en) 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
ATE533057T1 (de) 2005-09-20 2011-11-15 Osi Pharm Inc Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
US20080299113A1 (en) 2005-12-19 2008-12-04 Arnold Lee D Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
US8377636B2 (en) 2007-04-13 2013-02-19 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to kinase inhibitors
AU2008221604B2 (en) 2008-09-22 2010-04-22 Commonwealth Scientific And Industrial Research Organisation Temperature-responsive polymer particles in protein separation applications
WO2010120966A1 (en) 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors

Also Published As

Publication number Publication date
CA2601157A1 (en) 2006-09-28
EP1861715B1 (de) 2010-08-11
DE602006016085D1 (de) 2010-09-23
US8093011B2 (en) 2012-01-10
US20060211060A1 (en) 2006-09-21
US20160158235A1 (en) 2016-06-09
EP1861715A2 (de) 2007-12-05
JP2008533490A (ja) 2008-08-21
JP5085529B2 (ja) 2012-11-28
US9244058B2 (en) 2016-01-26
WO2006101925A2 (en) 2006-09-28
WO2006101925A3 (en) 2007-02-01
US20120157480A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
ATE477495T1 (de) Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
ATE533057T1 (de) Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
WO2008127718A3 (en) Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2009045389A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009045361A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
DE602005019294D1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
Rodrigo et al. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas
Adler et al. Metastatic pathways in patients with cutaneous melanoma
Wang et al. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder
Wagner et al. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
Sun et al. HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases
Luo et al. Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma
Torrisi et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17
Nie et al. Prognostic significance of long noncoding RNA Z38 as a candidate biomarker in breast cancer
Zhang et al. Overexpression of ubiquitin specific peptidase 14 predicts unfavorable prognosis in esophageal squamous cell carcinoma
Grupp et al. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy
Cao et al. Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma
Toss et al. Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ
Dai et al. Ubiquitin-specific peptidase 22, a histone deubiquitinating enzyme, is a novel poor prognostic factor for salivary adenoid cystic carcinoma
Song et al. Combined detection of HER2, Ki67, and GSTP1 genes on the diagnosis and prognosis of breast cancer
Qiao et al. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer
Lloyd et al. The histopathological and molecular features of breast carcinoma with tumour budding—A systematic review and meta-analysis
EP2449383B1 (de) Diagnoseverfahren zur vorhersage des krebsrekurrenzrisikos basierend auf histon-macroh2a-isoformen
Araz et al. Are preoperative serum CA15-3 levels different in breast cancer subgroups?
Cai et al. High-expression of ZBP-89 correlates with distal metastasis and poor prognosis of patients in clear cell renal cell carcinoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties